Heska Corp (NASDAQ:HSKA) Stock Holdings Cut by Grace & White Inc. NY

Grace & White Inc. NY reduced its position in shares of Heska Corp (NASDAQ:HSKA) by 1.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 55,985 shares of the medical research company’s stock after selling 1,000 shares during the quarter. Grace & White Inc. NY owned about 0.72% of Heska worth $4,768,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HSKA. Granite Investment Partners LLC bought a new position in Heska during the 1st quarter valued at $13,897,000. Redmile Group LLC boosted its stake in Heska by 14.3% during the 1st quarter. Redmile Group LLC now owns 226,013 shares of the medical research company’s stock valued at $19,238,000 after purchasing an additional 28,300 shares in the last quarter. Geode Capital Management LLC boosted its stake in Heska by 31.8% during the 4th quarter. Geode Capital Management LLC now owns 92,734 shares of the medical research company’s stock valued at $7,984,000 after purchasing an additional 22,378 shares in the last quarter. Martingale Asset Management L P boosted its stake in Heska by 120.9% during the 1st quarter. Martingale Asset Management L P now owns 29,602 shares of the medical research company’s stock valued at $2,521,000 after purchasing an additional 16,200 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in Heska by 330.6% during the 4th quarter. Millennium Management LLC now owns 18,659 shares of the medical research company’s stock valued at $1,607,000 after purchasing an additional 14,326 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have issued reports on HSKA. Canaccord Genuity reaffirmed a “speculative buy” rating and set a GBX 70 ($0.91) price target on shares of Bacanora Lithium in a research note on Monday, July 1st. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Guggenheim reissued a “buy” rating and set a $95.00 price objective (up from $90.00) on shares of VF in a research note on Thursday, May 23rd. Finally, BidaskClub raised WSFS Financial from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $97.67.

Shares of HSKA traded up $0.45 during trading hours on Wednesday, hitting $81.99. 1,303 shares of the company were exchanged, compared to its average volume of 59,432. The company has a market capitalization of $622.46 million, a P/E ratio of 57.77 and a beta of 0.96. The company has a quick ratio of 1.45, a current ratio of 2.66 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average is $81.22. Heska Corp has a one year low of $68.74 and a one year high of $114.50.

Heska (NASDAQ:HSKA) last released its quarterly earnings data on Tuesday, May 7th. The medical research company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.19. The business had revenue of $29.51 million during the quarter, compared to analyst estimates of $35.21 million. Heska had a return on equity of 8.36% and a net margin of 3.63%. Equities analysts anticipate that Heska Corp will post 0.03 earnings per share for the current fiscal year.

In other Heska news, Director Scott Humphrey bought 1,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The stock was acquired at an average price of $73.79 per share, with a total value of $73,790.00. Following the completion of the transaction, the director now directly owns 3,062 shares in the company, valued at approximately $225,944.98. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 14.00% of the company’s stock.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Featured Article: Calculate Your Return on Investment (ROI)

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.